Summary
A head-to-head study published in the New England Journal of Medicine found that Eli Lilly’s obesity drug, Zepbound, resulted in nearly 50% more weight loss compared to Novo Nordisk’s Wegovy, with participants losing an average of 50 pounds versus 33 pounds over 72 weeks. Zepbound, which targets two hormones (GLP-1 and GIP), showed significant health improvements for participants, while both medications reported mild to moderate side effects. Access and affordability remain concerns, but both drugs are essential in addressing the widespread obesity epidemic in the U.S., affecting about 40% of adults.
